MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer

References

• Wang HD, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–62.
   PubMed Web of Science ®Google Scholar
• Shen X, Xie B, Ma Z, et al. Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget. 2015;6:21730–21739.
   PubMedGoogle Scholar
• Wang C, Kar S, Lai X, et al. Triple negative breast cancer in Asia: an insider's view. Cancer Treat Rev. 2018;62:29–38.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767.
   PubMed Web of Science ®Google Scholar
• Irvin WJ, Carey LA. What is triple-negative breast cancer. Eur J Cancer. 2008;44:2799–2805.
   PubMed Web of Science ®Google Scholar
• Croci S, Nanni P, Palladini A, et al. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. Breast Cancer Res. 2015;17:70.
   PubMed Web of Science ®Google Scholar
• Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627–636.
   PubMed Web of Science ®Google Scholar
• O'Reilly EA, Gubbins L, Sharma S, et al. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015;3:257–275.
   PubMed Web of Science ®Google Scholar
• Bartsch R, Ziebermayr R, Zielinski CC, et al. Triple-negative breast cancer. Wien Med Wochenschr. 2010;160:174–181.
   PubMedGoogle Scholar
• Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–399.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ge Y, Fuchs E. miR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival. Genes Dev. 2014;28:2532–2546.
   PubMed Web of Science ®Google Scholar
• Wang Q, Qin J, Chen A, et al. Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer. Tumor Biol. 2015;36:3703–3708.
   PubMedGoogle Scholar
• Jin C, Yan B, Lu Q, et al. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumor Biol. 2016;37:7383–7394.
   PubMedGoogle Scholar
• Xu ST, Xu JH, Zheng ZR, et al. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed Pharmacother. 2017;96:14–21.
   PubMed Web of Science ®Google Scholar
• Kleivi SK, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015;21:1207–1214.
   PubMed Web of Science ®Google Scholar
• D'Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci. 2013;14:22202–22220.
   PubMed Web of Science ®Google Scholar
• Cascione L, Gasparini P, Lovat F, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013;8:e55910.
   PubMed Web of Science ®Google Scholar
• Bisso A, Faleschini M, Zampa F, et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle. 2013;12:1679–1687.
   PubMed Web of Science ®Google Scholar
• Taylor MA, Sossey-Alaoui K, Thompson CL, et al. TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 2013;123:150–163.
   PubMed Web of Science ®Google Scholar
• Niu J, Xue A, Chi Y, et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene. 2016;35:1302–1313.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang Y, Li X, et al. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1. Tumor Biol. 2013;34:1713–1722.
   PubMedGoogle Scholar
• Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011;10:507–517.
   PubMed Web of Science ®Google Scholar
• Eichelser C, Stückrath I, Müller V, et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014;5:9650–9663.
   PubMed Web of Science ®Google Scholar
• Fkih MI, Privat M, Trimeche M, et al. miR-10b, miR-26a, miR-146a And miR-153 expression in triple negative vs non triple negative breast cancer: potential biomarkers. Pathol Oncol Res. 2017;23:815–827.
   PubMed Web of Science ®Google Scholar
• Crippa E, Lusa L, De Cecco L, et al. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLOS One. 2014;9:e87039.
   PubMed Web of Science ®Google Scholar
• Garcia AI, Buisson M, Bertrand P, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3:279–290.
   PubMed Web of Science ®Google Scholar
• Yan LX, Wu QN, Zhang Y, et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011;13:R2.
   PubMed Web of Science ®Google Scholar
• Bai X, Han G, Liu Y, et al. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3. Biomed Pharmacother. 2018;103:1482–1489.
   PubMed Web of Science ®Google Scholar
• Xiong B, Lei X, Zhang L, et al. miR-103 regulates triple negative breast cancer cells migration and invasion through targeting olfactomedin 4. Biomed Pharmacother. 2017;89:1401–1408.
   PubMed Web of Science ®Google Scholar
• Wang C, Ju H, Shen C, et al. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med. 2015;8:15648–15656.
   PubMed Web of Science ®Google Scholar
• Chen H, Pan H, Qian Y, et al. MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer. 2018;17:4.
   PubMed Web of Science ®Google Scholar
• Li Z, Meng Q, Pan A, et al. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Oncotarget. 2017;8:19455–19466.
   PubMedGoogle Scholar
• Gasparini P, Cascione L, Fassan M, et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5:1174–1184.
   PubMedGoogle Scholar
• Tang W, Zhu J, Su S, et al. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLOS One. 2012;7:e51702.
   PubMed Web of Science ®Google Scholar
• Ren YQ, Fu F, Han J. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27. Med Sci Monit. 2015;21:1297–1303.
   PubMed Web of Science ®Google Scholar
• Jang MH, Kim HJ, Gwak JM, et al. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer. Hum Pathol. 2017;68:69–78.
   PubMed Web of Science ®Google Scholar
• Su CM, Wang MY, Hong CC, et al. miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene. 2017;36:5770.
   PubMed Web of Science ®Google Scholar
• Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285:21496–21507.
   PubMed Web of Science ®Google Scholar
• Aydoğdu E, Katchy A, Tsouko E, et al. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis. 2012;33:1502–1511.
   PubMed Web of Science ®Google Scholar
• Abdellatif M. Differential expression of microRNAs in different disease states. Circ Res. 2012;110:638–650.
   PubMed Web of Science ®Google Scholar
• Shin VY, Kwong A. Response to: Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'. Br J Cancer. 2016;114:e6.
   PubMed Web of Science ®Google Scholar
• Si C, Yu Q, Yao Y. Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5. Exp Ther Med. 2018;15:4515–4521.
   PubMed Web of Science ®Google Scholar
• Liu P, Tang H, Chen B, et al. miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 2015;357:384–392.
   PubMed Web of Science ®Google Scholar
• Yan M, Li X, Tong D, et al. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncol Rep. 2016;36:65–71.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang Y, Jasper J, et al. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. Oncotarget. 2016;7:20381–20394.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng X, Shen C, et al. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.
   PubMed Web of Science ®Google Scholar
• Jia Z, Liu Y, Gao Q, et al. miR-490-3p inhibits the growth and invasiveness in triple-negative breast cancer by repressing the expression of TNKS2. Gene. 2016;593:41–47.
   PubMed Web of Science ®Google Scholar
• Li D, Hu J, Song H, et al. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017;9:2276–2285.
   PubMed Web of Science ®Google Scholar
• Liu P, Ye F, Xie X, et al. mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget. 2016;7:35188–35198.
   PubMedGoogle Scholar
• Eades G, Wolfson B, Zhang Y, et al. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 2015;13:330–338.
   PubMed Web of Science ®Google Scholar
• Hou L, Chen M, Yang H, et al. MiR-940 inhibited cell growth and migration in triple-negative breast cancer. Med Sci Monit. 2016;22:3666–3672.
   PubMed Web of Science ®Google Scholar
• Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009;19:439–448.
   PubMed Web of Science ®Google Scholar
• Piovan C, Palmieri D, Di LG, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6:458–472.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Li Y, Tao H, et al. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Lett. 2018;433:199–209.
   PubMed Web of Science ®Google Scholar
• Li J, Lai Y, Ma J, et al. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer. BMC Cancer. 2017;17:745.
   PubMed Web of Science ®Google Scholar
• Shyamasundar S, Lim JP, Bay BH. miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1. Int J Oncol. 2016;49:2629–2636.
   PubMed Web of Science ®Google Scholar
• Yang ZX, Zhang B, Wei J, et al. MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression. Cancer Cell Int. 2018;18:16.
   PubMed Web of Science ®Google Scholar
• Shi Z, Li Y, Qian X, et al. MiR-340 inhibits triple-negative breast cancer progression by reversing EZH2 mediated miRNAs dysregulated expressions. J Cancer. 2017;8:3037–3048.
   PubMed Web of Science ®Google Scholar
• Hong L, Pan F, Jiang H, et al. miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7. Onco Targets Ther. 2016;9:2639–2648.
   PubMed Web of Science ®Google Scholar
• Zhou W, Song F, Wu Q, et al. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5. PLOS One. 2017;12:e0176395.
   PubMed Web of Science ®Google Scholar
• Tsouko E, Wang J, Frigo DE, et al. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcin. 2015;36:1051–1060.
   PubMed Web of Science ®Google Scholar
• Humphries B, Wang Z, Oom AL, et al. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis. Carcinogenesis. 2014;35:2254–2263.
   PubMed Web of Science ®Google Scholar
• Rhodes LV, Martin EC, Segar HC, et al. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget. 2015;6:16638–16652.
   PubMedGoogle Scholar
• Ren Y, Han X, Yu K, et al. microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. Mol Med Rep. 2014;10:315–321.
   PubMed Web of Science ®Google Scholar
• Howe EN, Cochrane DR, Cittelly DM, et al. miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLOS One. 2012;7:e49987.
   PubMed Web of Science ®Google Scholar
• Rogers TJ, Christenson JL, Greene LI, et al. Reversal of triple-negative breast cancer EMT by miR-200c decreases tryptophan catabolism and a program of immunosuppression. Mol Cancer Res. 2019;17:30–41.
   PubMed Web of Science ®Google Scholar
• Adams BD, Wali VB, Cheng CJ, et al. miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Res. 2016;76:927–939.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang X, Chao Z, et al. MiR-34a modulates ErbB2 in breast cancer. Cell Biol Int. 2017;41:93–101.
   PubMed Web of Science ®Google Scholar
• Mackiewicz M, Huppi K, Pitt JJ, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130:663–679.
   PubMed Web of Science ®Google Scholar
• Shen X, Si Y, Yang Z, et al. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. Med Oncol. 2015;32:361.
   PubMed Web of Science ®Google Scholar
• Liang Z, Bian X, Shim H. Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun. 2016;477:461–466.
   PubMed Web of Science ®Google Scholar
• Wang J, Tsouko E, Jonsson P, et al. miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. Mol Oncol. 2014;8:1690–1702.
   PubMed Web of Science ®Google Scholar
• Luo LJ, Yang F, Ding JJ, et al. MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. Gene. 2016;594:47–58.
   PubMed Web of Science ®Google Scholar
• Sossey-Alaoui K, Downs-Kelly E, Das M, et al. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int J Cancer. 2011;129:1331–1343.
   PubMed Web of Science ®Google Scholar
• Körner C, Keklikoglou I, Bender C, et al. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J Biol Chem. 2013;288:8750–8761.
   PubMed Web of Science ®Google Scholar
• Xiong H, Yan T, Zhang W, et al. miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. Cell Signal. 2018;44:33–42.
   PubMed Web of Science ®Google Scholar
• Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41:210–220.
   PubMed Web of Science ®Google Scholar
• Tan X, Peng J, Fu Y, et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 2014;16:435.
   PubMed Web of Science ®Google Scholar
• O'Brien K, Lowry MC, Corcoran C, et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015;6:32774–32789.
   PubMed Web of Science ®Google Scholar
• Bao L, Hazari S, Mehra S, et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012;180:2490–2503.
   PubMed Web of Science ®Google Scholar
• Liu X, Tang H, Chen J, et al. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015;6:20070–20083.
   PubMedGoogle Scholar
• Gao J, Li L, Wu M, et al. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLOS One. 2013;8:e65138.
   PubMed Web of Science ®Google Scholar
• Aakko S, Straume AH, Birkeland EE, et al. MYC-induced miR-203b-3p and miR-203a-3p control Bcl-xL expression and paclitaxel sensitivity in tumor cells. Transl Oncol. 2019;12:170–179.
   PubMed Web of Science ®Google Scholar
• Toraih EA, Mohammed EA, Farrag S, et al. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer patients. Mol Diagn Ther. 2015;19:179–190.
   PubMed Web of Science ®Google Scholar
• Gyparaki MT, Basdra EK, Papavassiliou AG. MicroRNAs as regulatory elements in triple negative breast cancer. Cancer Lett. 2014;354:1–4.
   PubMed Web of Science ®Google Scholar
• Farazi TA, Horlings HM, Ten HJJ, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71:4443–4453.
   PubMed Web of Science ®Google Scholar
• Hu J, Xu J, Wu Y, et al. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumor Biol. 2015;36:251–258.
   PubMedGoogle Scholar
• Ebrahimi A, Nikokar I, Zokaei M, et al. Design, development and evaluation of microRNA-199a-5p detecting electrochemical nanobiosensor with diagnostic application in triple negative breast cancer. Talanta. 2018;189:592–598.
   PubMed Web of Science ®Google Scholar
• Savad S, Mehdipour P, Miryounesi M, et al. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac J Cancer Prev. 2012;13:873–877.
   PubMedGoogle Scholar
• Liu Y, Cai Q, Bao PP, et al. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes. Breast Cancer Res Treat. 2015;152:183–191.
   PubMed Web of Science ®Google Scholar
• Dong G, Liang X, Wang D, et al. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 2014;31:57.
   PubMed Web of Science ®Google Scholar
• Yang L, Feng Y, Qi P, et al. Mechanism of serum miR-21 in the pathogenesis of familial and triple negative breast cancer. J Biol Regul Homeost Agents. 2016;30:1041–1045.
   PubMed Web of Science ®Google Scholar
• MacKenzie TA, Schwartz GN, Calderone HM, et al. Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. Am J Pathol. 2014;184:3217–3225.
   PubMed Web of Science ®Google Scholar
• Shen S, Sun Q, Liang Z, et al. A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLOS One. 2014;9:e100664.
   PubMed Web of Science ®Google Scholar
• Toyama T, Kondo N, Endo Y, et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 2012;42:256–263.
   PubMed Web of Science ®Google Scholar
• Cao Z-G, Li J-J, Ya L, et al. High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. Oncotarget. 2016;7:64900–64909.
   PubMedGoogle Scholar
• Svoboda M, Sana J, Redova M, et al. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012;7:31.
   PubMed Web of Science ®Google Scholar
• Yu H, Li H, Qian H, et al. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. Med Oncol. 2014;31:283.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Chen X, Zhu D, et al. Low expression of circulating microRNA-34c is associated with poor prognosis in triple-negative breast cancer. Yonsei Med J. 2017;58:697–702.
   PubMed Web of Science ®Google Scholar
• Deng L, Lei Q, Wang Y, et al. Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis. Oncotarget. 2017;8:108712–108725.
   PubMedGoogle Scholar
• Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013;139:223–229.
   PubMed Web of Science ®Google Scholar
• Shu D, Li H, Shu Y, et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano. 2015;9:9731–9740.
   PubMed Web of Science ®Google Scholar
• Devulapally R, Sekar NM, Sekar TV, et al. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano. 2015;9:2290–2302.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Kennell C, Lee JY, et al. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine. 2017;13:403–410.
   PubMed Web of Science ®Google Scholar
• Tomao F, Papa A, Zaccarelli E, et al. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther. 2015;8:177–193.
   PubMed Web of Science ®Google Scholar
• Althoff K, Lindner S, Odersky A, et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer. 2015;136:1308–1320.
   PubMed Web of Science ®Google Scholar
• Deng X, Cao M, Zhang J, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35:4333–4344.
   PubMed Web of Science ®Google Scholar
• Goyal R, Kapadia CH, Melamed JR, et al. Layer-by-layer assembled gold nanoshells for the intracellular delivery of miR-34a. Cell Mol Bioeng. 2018;11:383–396.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang J, Wang Y, et al. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine 2016;12:411–420.
   PubMed Web of Science ®Google Scholar
• Huang X, Taeb S, Jahangiri S, et al. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 2013;73:6972–6986.
   PubMed Web of Science ®Google Scholar
• Liang Z, Ahn J, Guo D, et al. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 2013;30:1008–1016.
   PubMed Web of Science ®Google Scholar
• Bockhorn J, Dalton R, Nwachukwu C, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013;4:1393.
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9:775–789.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A. 2012;109:E2110–2116.
   PubMed Web of Science ®Google Scholar
• Lehmann SM, Krüger C, Park B, et al. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci. 2012;15:827–835.
   PubMed Web of Science ®Google Scholar
• Wen D, Danquah M, Chaudhary AK, et al. Small molecules targeting microRNA for cancer therapy: promises and obstacles. J Control Release. 2015;219:237–247.
   PubMed Web of Science ®Google Scholar